Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 4, 2004, Pages 579-584

  Kralickova P ^a   Melichar, Bohuslav ^a   Malir F ^b   Roubal, T ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Xenobiochemic Laboratory   (Czech Republic)

Author keywords

Breast cancer; Chemotherapy; N acetyl D glucosaminidase; Nephrotoxicity; Zinc

Indexed keywords

ANTHRACYCLINE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; N ACETYL BETA GLUCOSAMINIDASE; PACLITAXEL; ZINC;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; HYPERZINCURIA; HYPOTHESIS; HYPOZINCEMIA; KIDNEY TUBULE DISORDER; METABOLIC DISORDER; NEPHROTOXICITY; PRIORITY JOURNAL; TOXICITY; TREATMENT OUTCOME; ULTRAFILTRATION; ZINC BLOOD LEVEL; ZINC URINE LEVEL;

ACETYLGLUCOSAMINIDASE; ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CREATINE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; MIDDLE AGED; TIME FACTORS; ZINC;

EID: 12544256872     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Levi F., Lucchini F., Negri E., Boyle P., La Vecchia C.: Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994. Eur. J. Cancer 35: 1477-1516, 1999.
2. Early Breast Cancer Trialists Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-932, 1998.
3. Early Breast Cancer Trialists Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998.
4. Fossati R., Confalonieri C., Torri V., et al.: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 35,510 women. J. Clin. Oncol. 16: 3439-3460, 1998.
5. Burtness B., Windsor S., Hoston B., et al.: Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. Cancer J. Sci. Am. 5: 224-229, 1999.
6. Fajardo L.F., Eltringham J.R., Stewart J.R., Klauber M.R.: Adriamycin nephrotoxicity. Lab. Invest. 43: 242-253, 1980.
7. Cameron E., Heys S.D., Bruce D., Eremin O., Hutcheon A.W., Whiting P.H.: Combination chemotherapy and renal enzyme and protein excretion in patients with breast cancer. Breast 6: 26-30, 1997.
8. Okasora T., Takikawa T., Utsunomiya Y., et al.: Suppressive effect of Superoxide dismutase on adrimycin nephropathy. Nephron 60: 199-203, 1992.
9. Zima T., Tesar V., Stípek S., et al.: The influence of cyclosporin on lipid peroxidation and Superoxide dismutase in adrimycin nephropathy in rats. Nephron 75: 464-468, 1996.
10. Price R.G.: The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin. Nephrol. 38: S14-S19, 1992.
11. Rustom R., Costigan M., Shenkin A., Bone J.M.: Proteinuria and renal tubular damage: Urinary N-acetyl-beta-D-glucosaminidase and isoenzymes in dissimilar renal disease. Am. J. Nephrol. 18: 179-185, 1998.
12. Melichar B., Jandik P., Malir F., et al.: Association between renal tubular cell dysfunction and increased urinary zinc excretion in cancer patients. Scand. J. Clin. Lab. Inv. 55: 149-152, 1994.
13. Allen J.I., Bell E., Boosalis M.G., et al.: Association between urinary zinc excretion and lymphocyte dysfunction in patients with lung cancer. Am. J. Med. 79: 209-215, 1985.
14. Voyatzoglou V., Mountokalakis T., Tsata-Voyatzoglou V., Koutselenis A., Skalkeas G.: Serum zinc levels and urinary zinc excretion in patients with bronchogenic carcinoma. Effects of tumor resection. Am. J. Surg. 144: 355-358, 1982.
15. Cohen E.P., Lemann J.: The role of the laboratory in the evaluation of kidney function. Clin. Chem. 37: 785-796, 1991.
16. Solichova D., Melichar B., Blaha V., et al.: Biochemical profile and survival in nonagenarians. Clin. Biochem. 34: 563-569, 2001.
17. Cockcroft D.W., Gault M.H.: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
18. Melichar B., Zangerle R., Artner-Dworzak E., Wachter H., Fuchs D.: Are disturbances of zinc metabolism in human immunodeficiency virus type 1 (HIV-1) infection cause by immune activation? Pteridines 4: 195-199, 1993.
19. Baer M.T., King J.C.: Tissue zinc levels and zinc excretion during experimental zinc depletion in young men. Am. J. Clin. Nutr. 39: 556-570, 1984.
20. Jung K.: Enzyme activities in urine: How should we express their excretion? Eur. J. Clin. Chem. Clin. Biochem. 29: 725-729, 1991.
21. Sadoff L.: Nephrotoxicity of streptozotocin (NSC-85998). Cancer Chemother. Rep. 54: 457-459, 1970.
22. Merouani A., Davidson S.A., Schrier R.W.: Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin lone. Am. J. Nephrol. 17: 53-58, 1997.
23. Nagai N., Kinoshita M., Ogata H., et al.: Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother. Pharmacol. 39: 131-137, 1996.
24. Hayashi M., Numaguchi M., Watabe H., Enomoto H., Yaoi Y.: Cisplatin-induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels. Acta Obstet. Gynecol. Scand. 76: 90-595, 1997.
25. Agaliotis D.P., Ballester O.F., Mattox T., et al.: Nephrotoxicity of high-dose ifosfamide/ carboplatin/ etoposide in adults undergoing autologous stem cell transplantation. Am. J. Med. Sci. 314: 292-298, 1997.
26. Marchewka Z., Dlugosz A.: Enzymes in urine as markers of nephrotoxicity of cytostatic agents and aminoglycoside antibiotics. Int. Urol. Nephrol. 30: 339-348, 1998.
27. Chmielnicka J., Szymanska J.A., Brzeznicka E.A., Kaluzynski A.: Changes in concentration of essential metals in kidneys and urine as indices of gentamicin nephrotoxicity in female Wistarrats. Pharmacol. Toxicol. 71: 185-189, 1992.
28. Yuzbasiyan-Gurkan V.A., Brewer G.J., Vander A.J., Guenther M.J., Prasad A.S.: Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia. Am. J. Hematol. 31: 87-90, 1989.
29. Kinlaw W.B., Levine A.S., Morley J.E., Silvis S.E., McClain C.J.: Abnormal zinc metabolism in type 11 diabetes mellitus. Am. J. Med. 75: 273-277, 1983.
30. Mahajan S.K., Abraham J., Migdal S.D., Abu-Hamdan D.K., McDonald F.D.: Effect of renal transplantation on zinc metabolism and taste acuity in uremia. Transplantation 38: 599-602, 1984.
31. Wellinghausen N., Kirchner H., Rink L.: The immunobiology of zinc, Immunol. Today 18: 519-521, 1997.
32. Pinto-Sietsma S.J., Janssen W.M.T., Hillege H.L., Navis G., de Zeeuw D., de Jong P.E.: Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J. Am. Soc. Nephrol. 11: 1882-1888, 2000.
33. Hostetter T.H., Rennke H.G., Brenner B.M.: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am. J. Med. 72: 375-380, 1982.
34. Carr S., Mbaya J.C., Thomas T., et al.: Increase in glomerular filtration rate in patients with insulin-independent diabetes and elevated erythrocyte sodium-lithium countertransport. N. Engl. J. Med. 322: 500-505, 1990.
35. Muller D., Sievers E., Eggert P.: Influence of hyperfiltration on the measurment of urinary N-acetyl-beta-D-glucosaminidase. Pediatr. Nephrol. 13: 519-523, 1999.